SERB Pharmaceuticals has successfully acquired Y-mAbs Therapeutics for $8.60 per share, strengthening its rare oncology portfolio with the addition of Danyelza®, a treatment for pediatric neuroblastoma.

Law firm Brodsky & Smith is investigating potential breaches of fiduciary duties by boards of several companies during recent merger and acquisition transactions, focusing on whether shareholders are receiving fair value.

Y-mAbs Therapeutics reported Q2 2025 results with revenue exceeding expectations but declining 14% year-over-year, primarily due to lower DANYELZA product sales. The company is being acquired by SERB Pharmaceuticals and is focusing on expanding its cancer therapy portfolio.

Law firm Monteverde & Associates is investigating the proposed sale of Y-mAbs Therapeutics to SERB Pharmaceuticals, where shareholders will receive $8.60 per share, to determine if the deal is fair.

Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies undergoing mergers or acquisitions.